Unidym Inc. Spins Off Ensysce Biosciences Inc. to Pursue Medical Therapeutic Applications of Carbon Nanotubes
Unidym, Inc, a majority-owned subsidiary of NASDAQ company Arrowhead Research Corporation, announced this month the formation of a spin-off company, Ensysce Biosciences Inc., that will focus on research into the medical therapeutic applications of carbon nanotubes. Unidym has licensed its extensive nanotechnology patent portfolio to Ensysce for this field of use and in return holds a significant equity position in Ensysce. The inception of Ensysce stems from the final research interests of the late Dr. Richard Smalley, the 1996 Nobel Laureate for Chemistry from Rice University, who was among the pioneers in considering the potential therapeutic applications for carbon nanotubes. Unidym acquired rights to Dr. Smalley's work in carbon nanotechnology through a corporate merger in April of last year.
Ensysce will immediately begin working with several of the world's leading chemists and clinicians in the field developing carbon nanotube based therapeutics. In parallel, Ensysce will immediately fund the research at Stanford University being led by Dr. Hongjie Dai and focused on the delivery of chemotherapy drugs such as taxol and doxorubicin using carbon nanotubes. Ensysce is also looking at novel ways of using carbon nanotubes to directly treat tumor cells.